Premium
Modified technique used in human bioassay of four butyrophenone derivatives in psychoneurotic patients
Author(s) -
Nodine John H.,
Bodi Tibor,
Levy Howard A.,
Siegler Peter E.,
Slap Joseph W.,
Mapp Yolanda,
Khorsandian Rostam
Publication year - 1962
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt196234432
Subject(s) - butyrophenone , bioassay , experimental animal , medicine , pharmacology , drug , biology , veterinary medicine , haloperidol , genetics , dopamine
Too often, following animal and acute human pharmacologic studies, insufficient information is available for the efficient and safe design of an adequately controlled double blind study in man. The single blind human bioassay of psychopharmacologic drugs, utilizing a spectrum of clinical conditions, may provide a rough estimate of the dose‐response relationship for clinical improvement, the dose‐response relationship for toxic effects, and an estimate of diagnostic categories in which potential usefulness may be established by double blind evaluation. This procedure avoids the expense of large numbers of toxicologic studies and provides the first screening for actual rejection of a drug from more complex and expensive thorough clinical investigation. The use of the modified technique is illustrated by studies with four butyrophenone derivatives (R‐1625, R‐1647, R‐1892, and R‐2167) in 151 patients. The dose‐response curves for these drugs, including the ED 50 and the TD 50 of each, were obtained in psychoneurotic outpatients and were found to correlate well with the ED 50 for animal conditioned avoidance behavior block and with the LD 50 in mice.